Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians (AHP), a community-driven, independent physician association (IPA) based in Southern California, will cover Cardio Diagnostics’ tests, Epi+Gen CHD™ and PrecisionCHD™, for their members with prior authorization beginning May 2026. AHP consists of an expansive network of primary care and specialists, hospitals, and ancillary providers serving managed care populations across Los Angeles and Orange County.

Providers will recommend Epi+Gen CHD™ or PrecisionCHD™ based on a patient’s medical history. Epi+Gen CHD™ assesses the three-year risk of a coronary heart disease (CHD) event, including a heart attack. PrecisionCHD™ aids in diagnosing CHD and provides the specific molecular drivers of CHD for each patient to help inform more personalized care.

Epi+Gen CHD™ and PrecisionCHD™ are simple, physician-ordered blood tests that do not require exposure to radiation or fasting. As a result, they seamlessly integrate into clinical workflows and do not require specialized infrastructure to administer.

“At Atlas Healthcare Physicians, we are committed to providing our physicians with innovative tools that support earlier detection, personalized treatment planning, and improved patient outcome,” said Tam Doan, MBA, Chief Operating Officer of Atlas Healthcare Physicians. “Our collaboration with Cardio Diagnostics reflects our shared commitment to expanding access to advanced cardiovascular diagnostics, empowering providers to make more informed clinical decisions, and helping patients better manager their heart health.”

“IPAs are uniquely positioned to drive better cardiovascular outcomes across their member populations and the right precision medicine tools can make a meaningful difference,” remarked Meesha Dogan, PhD, CEO and Co-Founder of Cardio Diagnostics. “By covering Epi+Gen CHD™ and PrecisionCHD™, AHP is giving its providers the ability to identify risk earlier, tailor care to each patient’s unique cardiovascular profile, and avoid costly downstream interventions that come from delayed or missed diagnoses. That’s a win for patients, for providers, and for the network.”

According to the California Department of Public Health, cardiovascular disease is a leading cause of death in California — and the largest economic burden on the state. While cardiovascular care places a significant cost challenge at both a state and national level, the cost of delaying action until symptoms manifest is far greater. This partnership reflects Cardio Diagnostics’ continued expansion of access to precision cardiovascular medicine across the United States.

About Atlas Healthcare Physicians

AHP is an IPA dedicated to improving the health and well-being of communities throughout Southern California. AHP partners with primary care and specialists, hospitals, and ancillary providers to deliver coordinated, high-quality healthcare to managed care populations across Los Angeles and Orange County. Through a commitment to provider support, operational excellence, and innovative healthcare solutions, AHP empowers its network to deliver accessible, patient-centered care while advancing quality outcomes and value-based healthcare initiatives.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.